Financial Performance - The company's operating revenue for Q1 2023 was ¥74,281,810.80, representing a decrease of 60.98% compared to the same period last year[2] - The net profit attributable to shareholders was -¥8,797,295.17, a decline of 121.45% year-over-year[2] - Total revenue for Q1 2023 was CNY 74,281,810.80, a decrease of 61.0% compared to CNY 190,362,813.69 in Q1 2022[16] - The net loss for Q1 2023 was CNY 8,741,237.41, compared to a net profit of CNY 41,015,898.04 in Q1 2022, indicating a significant decline in profitability[17] - Operating profit for Q1 2023 was CNY -8,164,495.07, a decrease from CNY 47,660,359.74 in the same period last year[17] Cash Flow - The net cash flow from operating activities increased by 57.71% to ¥32,825,677.22[2] - In Q1 2023, the cash inflow from operating activities was $113,846,781.35, a decrease of 46.4% compared to $212,236,160.54 in Q1 2022[21] - The net cash outflow from operating activities was $81,021,104.13, down from $191,422,525.03 in the same period last year, resulting in a net cash flow from operating activities of $32,825,677.22, an increase of 57.5% year-over-year[22] - The cash inflow from investment activities totaled $70,357,044.95, while cash outflow was $114,910,710.57, leading to a net cash flow from investment activities of -$44,553,665.62, an improvement from -$77,178,782.19 in Q1 2022[22] - The cash flow from financing activities resulted in a net outflow of $1,763,127.43, compared to a net outflow of $2,469,321.10 in the previous year, indicating a 28.5% reduction in cash outflow[22] Assets and Liabilities - The total assets at the end of Q1 2023 were ¥1,582,523,905.09, a decrease of 1.42% from the end of the previous year[3] - The company's total assets as of Q1 2023 were CNY 1,582,523,905.09, slightly down from CNY 1,605,340,593.15 in Q1 2022[15] - Total liabilities decreased to CNY 451,130,703.31 in Q1 2023 from CNY 465,208,287.98 in Q1 2022, a reduction of 3.0%[15] - The total current assets amounted to ¥808.87 million, down from ¥848.62 million at the end of 2022[13] - The total non-current assets amounted to CNY 773,656,320.74 in Q1 2023, compared to CNY 756,721,497.98 in Q1 2022, showing an increase of 2.2%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period was 7,029[10] - The largest shareholder, Yuan Jianhua, holds 30.98% of the shares, totaling 43,484,584 shares[10] Research and Development - Research and development expenses totaled ¥6,854,150.51, accounting for 9.23% of operating revenue, which is an increase of 4.14 percentage points[2] - Research and development expenses for Q1 2023 were CNY 6,854,150.51, down from CNY 9,684,707.76 in Q1 2022, a decrease of 29.0%[17] Market and Product Development - The company has no significant new product launches or technological developments reported in the current quarter[12] - There are no major market expansions or acquisitions mentioned in the latest report[12] - The company has not provided specific future guidance or performance outlook in the current report[12] Revenue Breakdown - Revenue from consumables was ¥72,990,100, a year-over-year decline of 61.16%[6] - Revenue from international customers decreased by 67.19% to ¥42,650,000, with specific declines in pipette tips and suction heads of 80.22% and 74.20%, respectively[7] - The comprehensive gross margin for consumable products dropped to 23.41%, down from 38.57% in the same period last year[8] Cash and Equivalents - The company's cash and cash equivalents as of March 31, 2023, were approximately ¥579.85 million, a decrease from ¥598.88 million at the end of 2022[13] - The total cash and cash equivalents at the end of Q1 2023 were $295,490,898.71, compared to $202,944,762.76 at the end of Q1 2022, reflecting a year-over-year increase of 45.5%[22] Other Financial Metrics - The issuance of convertible bonds in June 2022 resulted in an additional interest expense of ¥6,060,000 for the current period[8] - The company reported a basic and diluted earnings per share of CNY -0.06 for Q1 2023, compared to CNY 0.29 in Q1 2022[18] - Accounts receivable decreased to ¥85.85 million from ¥104.95 million year-over-year[13] - Inventory increased slightly to ¥126.04 million from ¥124.81 million at the end of 2022[13] - The company has not adopted new accounting standards for the current year, maintaining consistency in financial reporting[23]

1 证券代码：688026 证券简称：洁特生物 广州洁特生物过滤股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |---------------------|--------------------------|------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动 类别 | √特定对象调研 | □媒体采访 √业绩说明会 \n□现场参观 □其他 | □分析师会议 □新闻发布会 \n□路演活动 | | | | | 中泰证券资管、上海楹联投资、长城财富、博远基金、邦政资产、博 | | | | | 道基金、工银瑞信基金、招商证券、英大证券自营、敦和资产、凯丰 投资、华宝 ...

2022 年第三季度报告 证券代码：688026 证券简称：洁特生物 转债代码：118010 转债简称：洁特转债 广州洁特生物过滤股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 1 / 15 单位：元 币种：人民币 项目 本报告期 本报告期比 上年同期增 减变动幅度 (%) 年初至报告期末 年初至报告期 末比上年同期 增减变动幅度 (%) 营业收入 130,597,551.24 -43.76 480,300,424.47 -24.03 归属于上市公司股东的 净利润 15,634,167.75 -73.07 85,599,394 ...

证券代码：688026 证券简称：洁特生物 公告编号：2022-065 转债代码：118010 转债简称：洁特转债 广州洁特生物过滤股份有限公司 关于参加 2022 年广东辖区上市公司 投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步加强与投资者的互动交流，广州洁特生物过滤股份有限公司（以下 简称"公司"）将参加由广东证监局、广东上市公司协会、深圳市全景网络有限 公司共同举办的"2022 年广东辖区上市公司投资者网上集体接待日活动"，现 将有关事项公告如下： 本次集体接待日活动时间为 2022 年 9 月 22 日（星期四）15:50 至 16:50，活 动平台为深圳市全景网络有限公司提供的互联网平台。投资者可以登陆"全景路 演"网站（http://rs.p5w.net）参与公司本次投资者集体接待日活动。 届时公司高管将在线通过网络在线问答互动的形式，与投资者就公司业绩、 公司治理、发展战略、经营情况等投资者关注的问题进行沟通与交流。 欢迎广大投资者积极参与。 特此公告。 广州洁特生 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2022, with a total revenue of 500 million RMB, representing a 25% year-over-year growth[1]. - The company's basic earnings per share for the first half of 2022 was CNY 0.70, a decrease of 24.73% compared to CNY 0.93 in the same period last year[18]. - The company's revenue decreased by 12.57% year-on-year, primarily due to high revenue from pandemic-related products in the previous year[18]. - The company's net profit attributable to shareholders decreased by 24.66% year-on-year to CNY 69,965,226.46, while the net profit excluding non-recurring gains and losses fell by 31.53% to CNY 67,622,215.83, primarily due to a decline in revenue from pandemic-related products[19]. - The company's total revenue for the reporting period was CNY 349,702,873.23, representing a 12.57% decrease compared to CNY 399,962,167.63 in the previous year[19]. - The company achieved operating revenue of 349.70 million, a year-on-year decrease of 12.57% due to high base effects from the previous year and pandemic-related impacts[54]. - The company reported a total comprehensive income of CNY 72,161,987.20 for the first half of 2022, compared to CNY 108,316,644.50 in the same period of the previous year, indicating a decrease of about 33.33%[190]. Research and Development - Research and development investments increased by 30%, focusing on innovative filtration technologies[1]. - The company's R&D investment accounted for 5.71% of operating income, an increase of 1.72 percentage points compared to the previous year[18]. - The company is focusing on expanding its biological culture consumables segment, which showed significant growth[18]. - The company continues to prioritize R&D to enhance product offerings and market competitiveness[18]. - The company increased its R&D investment to approximately ¥19.98 million, a 25.20% increase compared to ¥15.96 million in the same period last year[33]. - The company applied for 25 patents and obtained 13 patents during the reporting period, bringing the total to 248 applications and 161 granted patents[31]. - The company has developed key technologies such as super-hydrophilic cell culture surfaces and 3D cell culture scaffolds, which are at the leading level in the domestic industry[47]. Market Expansion - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[1]. - The company is focused on developing new products such as large-capacity cell culture flasks and ultrafiltration centrifuge tubes to meet market demands in cell therapy and biopharmaceuticals[25]. - The company is actively developing new products, including large-capacity cell culture flasks and ultrafiltration centrifuge tubes, to meet market demands in cell therapy and vaccine development[54]. - The company is enhancing its domestic marketing network to improve sales service and increase market penetration among domestic customers[54]. Financial Position - The company has maintained a strong cash position, with cash reserves of 200 million RMB, ensuring liquidity for future investments[1]. - The company's net assets attributable to shareholders increased by 1.81% from the end of the previous year to CNY 989,361,149.13[19]. - The total assets of the company at the end of the reporting period amounted to 1,180.51 million, with equity attributable to shareholders of the parent company at 989.36 million[54]. - The company reported a significant increase in intangible assets by 395.22% to 60.03 million, mainly due to the acquisition of land use rights[73]. - The company’s total liabilities include significant leasing obligations, with the largest lease being for a warehouse in Guangzhou valued at 1,159.69 million RMB[121]. Sustainability and Environmental Commitment - The management highlighted a commitment to sustainability, aiming to reduce carbon emissions by 15% by 2025[1]. - The company utilizes medical-grade polymer materials for its biological laboratory disposable plastic consumables, emphasizing lightweight, temperature resistance, and pollution resistance[89]. - The implementation of solar photovoltaic power generation systems and central air conditioning water storage systems in some production workshops aims to reduce energy consumption and environmental impact[89]. - The company is committed to reducing carbon emissions through technological innovation and improving production efficiency, which has led to lower product costs[90]. Legal and Compliance - The company has ongoing litigation involving its wholly-owned subsidiary, Baifeier, against Guojij Smart Technology Co., with a claimed advance payment amount of 20,311,900 yuan, which was upheld by the Huangpu Court[111]. - The company has faced no significant changes in audit opinions or bankruptcy restructuring matters during the reporting period[112]. - There are no reported violations or penalties against the company or its executives during the reporting period[114]. Shareholder and Governance - The company has a stock incentive plan in place, which was approved in 2021, but there have been no updates or changes to its implementation[83]. - The company has committed to not providing unfair benefits to other entities or individuals, ensuring the protection of company interests[107]. - The company will ensure independent directors fulfill their responsibilities to protect the overall interests of the company and minority shareholders[108]. - The company has no non-operating fund occupation by controlling shareholders or related parties during the reporting period[110]. Operational Efficiency - The company aims to enhance its R&D capabilities to meet the growing demand for cell therapy products, ensuring compliance with rigorous risk assessment standards[40]. - The company plans to implement a share buyback program worth $20 million to enhance shareholder value[99]. - The company will improve the efficiency of fundraising management and ensure the effective implementation of fundraising projects[100]. - The company will enhance daily operational efficiency and reduce operational costs[100].

Financial Performance - The company's operating revenue for 2021 reached ¥855,658,196.26, representing a 69.80% increase compared to ¥503,933,836.45 in 2020[16]. - The net profit attributable to shareholders for 2021 was ¥171,157,975.38, a 43.38% increase from ¥119,371,464.55 in 2020[16]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥172,997,459.68, up 57.89% from ¥109,567,050.22 in 2020[16]. - The net cash flow from operating activities for 2021 was ¥221,383,765.99, an 18.03% increase from ¥187,566,736.11 in 2020[16]. - The total assets at the end of 2021 amounted to ¥1,180,454,882.67, a 21.73% increase from ¥969,709,074.32 at the end of 2020[16]. - The net assets attributable to shareholders at the end of 2021 were ¥971,819,365.19, reflecting a 21.95% increase from ¥796,893,187.84 at the end of 2020[16]. - The company's basic and diluted earnings per share increased by 40.16% to CNY 1.71 compared to the previous year[17]. - The net profit attributable to shareholders grew by 43.38% to CNY 69.80 million, primarily due to increased sales of disposable plastic consumables in biological laboratories[18]. - The weighted average return on equity rose by 3.05 percentage points to 19.39% compared to the previous year[17]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 6.00 CNY per 10 shares, totaling 60,000,000 CNY, which represents 35.06% of the net profit attributable to shareholders for 2021[4]. - The profit distribution plan has been approved by the board and awaits shareholder meeting approval[4]. - The cumulative distributable profit for the parent company as of December 31, 2021, was CNY 401.0929 million[156]. - The company plans to distribute at least 10% of the annual distributable profit as dividends, with higher percentages based on the company's development stage and capital expenditure plans[155]. Research and Development - The company applied for 28 patents during the reporting period, including 7 invention patents and 17 utility model patents[27]. - The company achieved a total R&D investment of ¥43,840,335.07, representing an increase of 83.46% compared to the previous year[51]. - R&D investment accounted for 5.12% of total revenue, up from 4.74% in the previous year, marking an increase of 0.38 percentage points[51]. - The number of R&D personnel increased to 150, accounting for 10.48% of the total workforce, up from 6.87% the previous year[69]. - The company is planning to continue increasing R&D investment in response to market demands in cell therapy, biomedicine, infectious disease detection, and vaccine development[27]. Market Expansion and Strategy - The company aims to expand its market share in the biological laboratory consumables industry and penetrate the medical consumables and medical devices sectors[27]. - The company is focused on expanding its market presence and enhancing product development capabilities[10]. - The company plans to enhance its domestic marketing network and expand its market share, aiming for higher penetration rates of domestic products[28]. - The company is exploring overseas brand marketing channels and enhancing its production capabilities through smart manufacturing technologies[28]. - The company aims to strengthen its brand influence and market presence, targeting an increase in domestic market penetration and the establishment of overseas marketing channels within the next three years[122]. Production and Operational Efficiency - The company is focusing on expanding its production capacity to alleviate bottlenecks, with increased demand for disposable plastic consumables in the life sciences sector[28]. - The company has implemented automation in the production of protective masks, establishing a fully automated operation from material feeding to packaging[45]. - The company’s investment in automation technology has led to a significant reduction in manual intervention in production processes, enhancing overall efficiency[58]. - The company has established a flexible customized production capability, allowing for advanced product design solutions and continuous development of high-end consumables, effectively enhancing profitability and core competitiveness[72]. Compliance and Governance - The company has received a standard unqualified audit report from Tianjian Accounting Firm[3]. - The company has not yet achieved profitability since its listing[3]. - The company has detailed potential risks in the annual report, which can be found in the "Management Discussion and Analysis" section[3]. - The company has no violations of decision-making procedures for external guarantees[5]. - The company has not reported any significant changes in its governance structure or independence from its controlling shareholder[125]. Risks and Challenges - The company faces risks in new product market promotion, as new products may take time to achieve large-scale sales, limiting short-term profitability[78]. - Domestic market expansion is challenged by the dominance of imported brands, which may hinder the company's ability to significantly increase its market share[78]. - The company is exposed to overseas sales risks due to geopolitical uncertainties and trade policies, particularly affecting its competitiveness in the U.S. market[79]. - The demand for protective products has declined post-pandemic, leading to potential legal disputes and asset impairment risks due to unsold inventory[80]. - The company is at risk of raw material price fluctuations, as major materials are derived from petroleum, which is subject to price volatility[82]. Environmental and Social Responsibility - The company has implemented measures to reduce carbon emissions, focusing on energy conservation and technological innovation to improve production efficiency[183]. - The company donated 10 million KN95 masks to support pandemic prevention efforts in Guangzhou[186]. - The company has established a quality control management system certified by ISO 9001:2015 and ISO 13485:2016, ensuring no major product quality issues reported[192]. Shareholder and Management Policies - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 7.1365 million RMB[138]. - The company has established a compensation and assessment committee to evaluate senior management based on performance standards, continuously improving long-term incentive policies[170]. - The company has a remuneration policy where the compensation for senior management consists of basic salary and year-end bonuses, with the basic salary determined by job level and responsibilities[138]. - The company has committed to maximizing shareholder value while adhering to legal and regulatory requirements for profit distribution[187].

Revenue and Profit - Revenue for Q1 2022 was CNY 190,362,813.69, representing a year-over-year increase of 9.42%[2] - Net profit attributable to shareholders decreased by 14.64% to CNY 41,015,898.04 compared to the same period last year[2] - Basic and diluted earnings per share were both CNY 0.41, down 14.58% year-over-year[2] - Net profit for Q1 2022 was ¥41,015,898.04, a decrease of 14.66% from ¥48,051,641.98 in Q1 2021[14] - Earnings per share for Q1 2022 was ¥0.41, down from ¥0.48 in Q1 2021[15] Expenses and Costs - R&D expenses totaled CNY 9,684,707.76, an increase of 102.82% year-over-year, accounting for 5.09% of revenue[2][5] - Total operating costs for Q1 2022 were ¥143,124,159.20, up from ¥112,539,775.03 in Q1 2021, representing a 27.19% increase[14] - Research and development expenses for Q1 2022 were ¥9,684,707.76, significantly higher than ¥4,775,140.09 in Q1 2021, marking an increase of 102.56%[14] - The company reported a financial expense of ¥1,861,898.50 in Q1 2022, compared to a financial income of ¥1,476,820.70 in Q1 2021[14] Assets and Liabilities - Total assets at the end of Q1 2022 were CNY 1,214,895,768.46, up 2.92% from the end of the previous year[3] - The company's cash and cash equivalents decreased to RMB 202,944,762.76 from RMB 263,468,195.75, representing a decline of about 22.9%[9] - Accounts receivable increased to RMB 150,278,082.51 from RMB 141,090,377.22, showing a growth of approximately 6.5%[9] - Inventory rose to RMB 128,398,777.17 from RMB 123,118,175.57, indicating an increase of about 4.3%[9] - Non-current assets totaled RMB 690,164,465.88, up from RMB 610,492,350.22, marking an increase of approximately 13.1%[10] - The company's total liabilities included accounts payable of RMB 45,596,561.09, down from RMB 67,360,606.60, a decrease of about 32.3%[10] - The company reported a decrease in other payables from RMB 1,822,979.80 to RMB 10,381,334.39, reflecting a significant increase of approximately 471.5%[10] - The company’s total current assets were reported at RMB 524,731,302.58, down from RMB 569,962,532.45, reflecting a decrease of approximately 7.9%[9] - Total liabilities decreased to ¥196,987,467.94 in Q1 2022 from ¥208,635,517.48 in Q1 2021, a reduction of 5.88%[14] - Total equity attributable to shareholders increased to ¥1,017,908,300.52 in Q1 2022 from ¥971,819,365.19 in Q1 2021, an increase of 4.73%[14] Cash Flow - The net cash flow from operating activities was CNY 20,813,635.51, a significant increase from the previous year's negative cash flow[5] - Cash received from sales of goods and services in Q1 2022 was ¥187,269,990.41, compared to ¥138,148,919.16 in Q1 2021, reflecting a growth of 35.51%[17] - Total cash inflow from operating activities reached $212,236,160.54, while cash outflow was $191,422,525.03, resulting in a net increase of $20,813,635.51[18] - Cash flow from investing activities was negative at -$77,178,782.19, compared to -$54,054,106.13 in the same period last year, reflecting increased investment expenditures[18] - Cash flow from financing activities resulted in a net outflow of -$2,469,321.10, a decrease from a net inflow of $3,058,113.22 in the previous year[19] - The company received $3,034,654.16 in tax refunds, contributing to the overall cash inflow from operating activities[18] - Cash paid to employees was $34,266,794.49, an increase from $30,462,781.41 in the previous year, indicating higher personnel costs[18] - Cash paid for taxes amounted to $8,790,573.34, compared to $7,684,658.77 in the same period last year, reflecting an increase in tax obligations[18] Investments and Capital Expenditures - The company has ongoing investments in long-term equity amounting to RMB 49,807,269.40, compared to RMB 30,735,681.62 previously, indicating a growth of approximately 62.1%[10] - The company invested $57,178,782.19 in fixed assets, up from $50,054,106.13 in the previous year, indicating ongoing capital expenditures[18] Shareholder Information - The total number of common shareholders at the end of the reporting period was 4,615[6] - Shareholders' equity attributable to the parent company increased by 4.74% to CNY 1,017,908,300.52[3] Miscellaneous - The company reported non-recurring gains of CNY 1,449,082.21 after tax[4] - The weighted average return on equity decreased by 1.73 percentage points to 4.12%[2] - Deferred income tax liabilities remained stable at ¥1,961,645.33 in both Q1 2022 and Q1 2021[14] - The impact of exchange rate changes on cash and cash equivalents was -$1,688,965.21, compared to -$118,947.16 in the previous year, highlighting currency fluctuations' effect on cash reserves[19]

2021 年第三季度报告 证券代码：688026 证券简称：洁特生物 广州洁特生物过滤股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 1 / 15 单位：元 币种：人民币 项目 本报告期 本报告期比上 年同期增减变 动幅度(%) 年初至报告期 末 年初至报告期末 比上年同期增减 变动幅度(%) 营业收入 232,229,837.08 113.23 632,192,004.71 67.44 归属于上市公司股东的 净利润 58,061,420.43 203.29 150,928,316.74 16.79 归属于上市公司股东的 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2021, with a year-on-year growth of 25%[1]. - The company's operating revenue for the first half of 2021 was approximately CNY 399.96 million, representing a 48.87% increase compared to CNY 268.66 million in the same period last year[18]. - The net profit attributable to shareholders decreased by 15.65% to CNY 92.87 million from CNY 110.09 million year-on-year[18]. - The company reported a total revenue of 6,220.00 million RMB for the first half of 2021, with a net profit of 1,596.31 million RMB, representing a profit margin of approximately 25.7%[42]. - The net profit from the biological laboratory consumables business was 108.32 million yuan, reflecting a year-on-year growth of 132.98%[52]. - The company reported a total comprehensive income of ¥92,866,896.31 for the first half of 2021[157]. Research and Development - Research and development expenditures have increased by 30%, reflecting the company's commitment to innovation[1]. - R&D investment increased by 55.41% year-on-year, totaling approximately ¥15.96 million, driven by the development of disposable plastic consumables for biological laboratories[32]. - The R&D expenditure as a percentage of operating revenue increased to 3.99%, up by 0.17 percentage points from the previous year[19]. - The company has developed nearly a thousand types of products, focusing on cell culture and liquid handling consumables, and has responded to COVID-19 by rapidly producing essential testing materials[26]. - The company aims to provide comprehensive solutions for biological laboratory consumables, leveraging its advanced polymer material modification technologies[26]. Market Expansion and Strategy - The company is expanding its market presence, targeting new regions with a planned investment of 50 million yuan in marketing efforts[1]. - The company has implemented new strategies to improve operational efficiency, aiming for a 10% reduction in costs by the end of the year[1]. - The company aims to enhance its market position by expanding its product offerings in the biomedical protective equipment sector[46]. - The company is focused on creating a comprehensive ecosystem for cell therapy, including consumables and processing equipment, to support the growing market[36]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[146]. Product Development and Innovation - New product development includes the launch of a next-generation filtration system, expected to enhance market competitiveness[1]. - The company has reported a significant focus on developing new products in response to the pandemic, including disposable virus sampling tubes and PCR plates[26]. - The company launched several new products, including deep well plates, PCR tubes, and virus sampling tubes, which have received CE certification[29]. - The company’s automated production line for disposable serum pipettes has improved production efficiency by 1.5 times[32]. - The company is developing a dual-layer membrane purification column for nucleic acid extraction, which improves extraction efficiency and has a product quality rate of 121.35%[38]. Financial Position and Assets - Total assets increased by 15.87% to CNY 1.12 billion from CNY 969.71 million at the end of the previous year[18]. - The net assets attributable to shareholders rose by 10.69% to CNY 882.05 million compared to CNY 796.89 million at the end of the previous year[18]. - The total current assets as of June 30, 2021, amounted to CNY 620,846,494.75, an increase from CNY 593,357,600.55 at the end of 2020, reflecting a growth of approximately 4.3%[139]. - Total liabilities increased to ¥239,087,365.08 from ¥121,807,087.44, indicating a rise of 96.5%[144]. - The total equity attributable to the parent company was ¥796,893,187.84, unchanged from the previous year[157]. Risks and Challenges - The company has identified key risks in its operations, including supply chain disruptions, and has outlined mitigation strategies[1]. - The company faces risks related to the concentration of major customers, which could impact operational performance if customer needs are not met[56]. - The market demand for disposable plastic consumables may significantly decrease post-COVID-19, particularly for products related to vaccine development and nucleic acid testing[60]. - The company is exposed to risks from fluctuations in raw material prices, particularly for polystyrene, polypropylene, and polyethylene, which are linked to oil prices[58]. - The company has not established a foreign exchange hedging mechanism, making it vulnerable to fluctuations in the RMB/USD exchange rate[59]. Corporate Governance and Compliance - The board has confirmed that there are no non-operational fund usages by controlling shareholders[1]. - The company has not disclosed any non-operational fund occupation by controlling shareholders or related parties during the reporting period[99]. - The company has committed to ensuring that its IPO prospectus does not contain any false statements or misleading information[93]. - The controlling shareholder and actual controller have made commitments to not interfere with the company's management activities and to protect the company's interests[95]. - The company emphasizes a stable and continuous profit distribution policy, prioritizing cash dividends when conditions allow, with a minimum of 10% of distributable profits allocated for cash dividends in any given year[96]. Environmental and Social Responsibility - The company has implemented various environmental protection measures, ensuring compliance with local regulations and obtaining necessary permits[81]. - The company has adopted solar photovoltaic systems and a central air conditioning water storage system to enhance energy efficiency and reduce environmental impact[84]. - During the recent COVID-19 outbreak in Guangzhou, the company committed to donating 10 million KN95 masks, with 5.53 million delivered by June 30, actively supporting local pandemic control efforts[85]. - The company has not faced any significant environmental penalties or incidents during the reporting period[81]. - The company’s waste management practices include proper handling of hazardous waste and compliance with environmental standards[82]. Legal Matters - The company is involved in significant litigation, including a lawsuit against Guo Ji Intelligent Technology Co., Ltd. for a contract dispute involving a prepayment amount of 20,311,900 RMB[99]. - The company has filed a counterclaim in a lawsuit with Zhou Hao regarding a sales contract, with the total amount in dispute reaching 12 million RMB[99]. - The company is pursuing legal action against Shenzhen Zhen Tong Trading Co., Ltd. for trademark infringement, seeking damages of 4,000,000 RMB and additional legal fees totaling 115,874.44 RMB[101]. - The company has reported a total of 4,115,874.44 RMB in claims against Zhen Tong Trading and Le Cheng (Shenzhen) Medical Technology Co., Ltd. in an ongoing case[101]. - The company has experienced a significant number of lawsuits related to its mask sales, indicating ongoing operational challenges in the market[99].

Financial Performance - Net profit attributable to shareholders increased by 43.52% to CNY 48,051,641.98 year-on-year[6] - Operating revenue surged by 133.58% to CNY 173,974,009.06 compared to the same period last year[6] - Basic earnings per share increased by 29.73% to CNY 0.48[6] - The weighted average return on equity increased by 0.43 percentage points to 5.85%[6] - The net profit for Q1 2021 was RMB 54.71 million, representing a year-on-year growth of 213.50%[14] - Total operating revenue for Q1 2021 was RMB 174 million, up 133.58% compared to the same period last year[14] - The net profit for Q1 2021 reached RMB 54,714,438.52, up 213.5% from RMB 17,452,772.29 in Q1 2020[39] - The operating profit for Q1 2021 was RMB 63,859,274.49, representing a growth of 232.5% compared to RMB 19,246,908.58 in Q1 2020[37] Assets and Liabilities - Total assets increased by 10.17% to CNY 1,068,331,678.62 compared to the end of the previous year[6] - The company's current assets totaled CNY 637,279,399.47 as of March 31, 2021, compared to CNY 593,357,600.55 at the end of 2020, indicating an increase of about 7.4%[24] - Total liabilities as of March 31, 2021, were CNY 223,386,848.80, up from CNY 172,815,886.48, representing a growth of about 29.2%[26] - The company's equity attributable to shareholders increased to CNY 844,944,829.82 from CNY 796,893,187.84, reflecting an increase of approximately 6%[26] - Total assets as of Q1 2021 amounted to ¥1,020,522,784.75, up from ¥903,556,874.38 in the previous year, representing a growth of approximately 12.9%[30] - Total liabilities for Q1 2021 were ¥184,058,559.29, compared to ¥121,807,087.44 in Q1 2020, indicating an increase of about 51.0%[30] Cash Flow - The net cash flow from operating activities decreased by 101.63% to -CNY 1,228,119.17 compared to the previous year[6] - The cash flow from operating activities showed a net outflow of RMB 1,228,119.17 in Q1 2021, contrasting with a net inflow of RMB 75,427,925.93 in Q1 2020[40] - The total cash and cash equivalents at the end of Q1 2021 were RMB 247,614,375.00, down from RMB 490,703,028.03 at the end of Q1 2020[40] - The cash outflow from investing activities in Q1 2021 was RMB 54,054,106.13, compared to RMB 17,462,814.20 in Q1 2020[40] - Cash inflow from financing activities in Q1 2021 was RMB 393,275,943.40, while cash outflow was RMB 941,886.78, resulting in a net cash inflow of RMB 392,334,056.62[43] Research and Development - The proportion of R&D investment to operating revenue decreased by 0.38 percentage points to 2.74%[6] - The company's research and development expenses grew by 105.21% to RMB 4.78 million, reflecting ongoing investment in projects[15] - Research and development expenses for Q1 2021 were ¥4,775,140.09, compared to ¥2,326,976.91 in Q1 2020, indicating an increase of about 105.5%[33] Shareholder Information - The number of shareholders reached 6,418 at the end of the reporting period[10] - The top shareholder, Yuan Jianhua, holds 31.00% of the shares[11] Market and Product Development - The company is focused on expanding its market presence and developing new products and technologies[21] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[34] Legal and Compliance - The company faced a legal dispute involving a prepayment of RMB 20.31 million related to mask equipment contracts[18] - The implementation of the new leasing standard began on January 1, 2021, affecting the financial reporting of the company[53]